School-Age Outcomes of Antenatal Magnesium Sulphate in Preterm Infants
Background: Antenatal magnesium sulphate (MgSO<sub>4</sub>) therapy given to women at risk of preterm birth reduced the risk of cerebral palsy in early childhood. However, its effect on longer-term neurological outcomes remains uncertain. This study aimed to assess the effects of antenat...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Children |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9067/10/8/1324 |
| _version_ | 1797585105203494912 |
|---|---|
| author | Akira Kobayashi Masato Ito Erika Ota Fumihiko Namba |
| author_facet | Akira Kobayashi Masato Ito Erika Ota Fumihiko Namba |
| author_sort | Akira Kobayashi |
| collection | DOAJ |
| description | Background: Antenatal magnesium sulphate (MgSO<sub>4</sub>) therapy given to women at risk of preterm birth reduced the risk of cerebral palsy in early childhood. However, its effect on longer-term neurological outcomes remains uncertain. This study aimed to assess the effects of antenatal MgSO<sub>4</sub> therapy on school-age outcomes of preterm infants. Methods: We conducted a systematic review and meta-analysis. We searched MEDLINE, EMBASE, CENTRAL, and CINAHL for randomized controlled trials (RCTs). Two reviewers independently evaluated the eligibility for inclusion and extracted data. Results: Ten RCTs were included. Only two of them were on school-age outcomes. Antenatal MgSO<sub>4</sub> therapy had no impact on cerebral palsy, hearing impairment, neurosensory disability, and death at school-age. Meta-analysis on mental retardation and visual impairment was not able to be performed due to different methods of evaluation. In the analysis of short-term outcomes conducted as secondary outcomes, antenatal MgSO<sub>4</sub> therapy increased the risk of maternal adverse events with any symptom (3 RCTs; risk ratio 2.79; 95% confidence interval 1.10 to 7.05, low certainty of evidence) but was not associated with any neonatal symptoms. Conclusions: The number of cases was insufficient to determine the impact of antenatal MgSO<sub>4</sub> therapy on school-age outcomes. Further accumulation of long-term data is required. |
| first_indexed | 2024-03-11T00:02:08Z |
| format | Article |
| id | doaj.art-4a8f406b7e474092b58ab263eecbb252 |
| institution | Directory Open Access Journal |
| issn | 2227-9067 |
| language | English |
| last_indexed | 2024-03-11T00:02:08Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Children |
| spelling | doaj.art-4a8f406b7e474092b58ab263eecbb2522023-11-19T00:39:46ZengMDPI AGChildren2227-90672023-07-01108132410.3390/children10081324School-Age Outcomes of Antenatal Magnesium Sulphate in Preterm InfantsAkira Kobayashi0Masato Ito1Erika Ota2Fumihiko Namba3General Center for Perinatal, Maternal and Neonatal Medicine, Niigata University Medical and Dental Hospital, Niigata 951-8520, JapanDepartment of Pediatrics, Akita University Graduate School of Medicine, Akita 010-8543, JapanGlobal Health Nursing, Graduate School of Nursing Science, St. Luke’s International University, Chuo-ku, Tokyo 104-0044, JapanDepartment of Pediatrics, Saitama Medical Center, Saitama Medical University, Saitama 350-8550, JapanBackground: Antenatal magnesium sulphate (MgSO<sub>4</sub>) therapy given to women at risk of preterm birth reduced the risk of cerebral palsy in early childhood. However, its effect on longer-term neurological outcomes remains uncertain. This study aimed to assess the effects of antenatal MgSO<sub>4</sub> therapy on school-age outcomes of preterm infants. Methods: We conducted a systematic review and meta-analysis. We searched MEDLINE, EMBASE, CENTRAL, and CINAHL for randomized controlled trials (RCTs). Two reviewers independently evaluated the eligibility for inclusion and extracted data. Results: Ten RCTs were included. Only two of them were on school-age outcomes. Antenatal MgSO<sub>4</sub> therapy had no impact on cerebral palsy, hearing impairment, neurosensory disability, and death at school-age. Meta-analysis on mental retardation and visual impairment was not able to be performed due to different methods of evaluation. In the analysis of short-term outcomes conducted as secondary outcomes, antenatal MgSO<sub>4</sub> therapy increased the risk of maternal adverse events with any symptom (3 RCTs; risk ratio 2.79; 95% confidence interval 1.10 to 7.05, low certainty of evidence) but was not associated with any neonatal symptoms. Conclusions: The number of cases was insufficient to determine the impact of antenatal MgSO<sub>4</sub> therapy on school-age outcomes. Further accumulation of long-term data is required.https://www.mdpi.com/2227-9067/10/8/1324magnesium sulfatepreterm infantsoutcome assessment |
| spellingShingle | Akira Kobayashi Masato Ito Erika Ota Fumihiko Namba School-Age Outcomes of Antenatal Magnesium Sulphate in Preterm Infants Children magnesium sulfate preterm infants outcome assessment |
| title | School-Age Outcomes of Antenatal Magnesium Sulphate in Preterm Infants |
| title_full | School-Age Outcomes of Antenatal Magnesium Sulphate in Preterm Infants |
| title_fullStr | School-Age Outcomes of Antenatal Magnesium Sulphate in Preterm Infants |
| title_full_unstemmed | School-Age Outcomes of Antenatal Magnesium Sulphate in Preterm Infants |
| title_short | School-Age Outcomes of Antenatal Magnesium Sulphate in Preterm Infants |
| title_sort | school age outcomes of antenatal magnesium sulphate in preterm infants |
| topic | magnesium sulfate preterm infants outcome assessment |
| url | https://www.mdpi.com/2227-9067/10/8/1324 |
| work_keys_str_mv | AT akirakobayashi schoolageoutcomesofantenatalmagnesiumsulphateinpreterminfants AT masatoito schoolageoutcomesofantenatalmagnesiumsulphateinpreterminfants AT erikaota schoolageoutcomesofantenatalmagnesiumsulphateinpreterminfants AT fumihikonamba schoolageoutcomesofantenatalmagnesiumsulphateinpreterminfants |